Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program
May 11, 2021 08:00 ET
|
HalioDx
Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced rectal cancerExpert clinical centers already involved worldwide in this new Innovation...
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center
October 09, 2020 08:00 ET
|
HalioDx
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients Marseille, France, October 9,...
DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure
July 15, 2019 09:00 ET
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, July 15, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced the start of a phase 2 randomized, double-blind, placebo-controlled trial to evaluate...
Cohera Medical Inc.® Awarded Patent on its Biodegradable Sealant Technology
April 25, 2018 07:00 ET
|
Cohera Medical, Inc.
RALEIGH, N.C., April 25, 2018 (GLOBE NEWSWIRE) -- Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that the U.S. Patent and...
ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China
January 18, 2018 01:00 ET
|
ASLAN Pharmaceuticals
SINGAPORE , Jan. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Announces Shortened Timeline to Commercialisation for Varlitinib in China
January 08, 2018 01:00 ET
|
ASLAN Pharmaceuticals
SINGAPORE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 04, 2018 02:00 ET
|
ASLAN Pharmaceuticals
SINGAPORE, Jan. 04, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for Varlitinib From Array BioPharma
January 03, 2018 03:00 ET
|
ASLAN Pharmaceuticals
SINGAPORE, Jan. 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan...
Colon Cancer Alliance and Allsup Help Former Workers Avoid Disability Backlog
August 15, 2017 10:51 ET
|
Allsup
Belleville, Illinois, Aug. 15, 2017 (GLOBE NEWSWIRE) -- The Colon Cancer Alliance and Allsup, a national provider of Social Security Disability Insurance (SSDI) representation, today announced a...
Carcinoembryonic Antigen Market to hit $2.7bn by 2023: Global Market Insights, Inc.
April 20, 2017 06:30 ET
|
Global Market Insights, Inc
Ocean View, Delaware, April 20, 2017 (GLOBE NEWSWIRE) -- The research report “Carcinoembryonic Antigen (CEA) Market Size By Application (Colorectal, Pancreatic, Ovarian, Breast, Thyroid Cancer),...